Form 4: Sage Therapeutics CEO Awarded Stock Options Under 2024 Equity Incentive Plan
SEC Form 4
Sage Therapeutics CEO, Barry E. Greene, was granted 174,000 stock options under the company's 2024 Equity Incentive Plan.
Summary
- Barry E. Greene, the President and CEO of Sage Therapeutics, was granted 174,000 stock options on January 16, 2025.
- These options were awarded under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan.
- The options have an exercise price of $6.97 per share.
- 43,500 of the options will vest on the one-year anniversary of the grant date, January 16, 2026.
- The remaining 130,500 options will vest in 36 equal monthly installments after the initial vesting date.
- The options expire on January 16, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.
Positives
- The stock option grant aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term performance and retention of the CEO.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in the biotech industry, often with similar vesting schedules.
- The vesting schedule of one year cliff vesting followed by monthly vesting is a common practice.
- The exercise price of $6.97 is not directly comparable without knowing the current market price of the stock.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date of Power of Attorney authorization for Barry E. Greene. |
| 2025-01-16 | Date of stock option grant to Barry E. Greene. |
| 2025-01-21 | Date of filing of the Form 4. |
| 2026-01-16 | First vesting date for 43,500 stock options. |
| 2035-01-16 | Expiration date of the stock options. |
Keywords
stock options, equity incentive plan, executive compensation, vesting, Sage Therapeutics, Barry E. Greene
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.